http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111517980-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-52
filingDate 2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-111517980-B
titleOfInvention N- [8- (2-hydroxybenzoyl) amino ] caprylic acid monopotassium crystal type compound, preparation method and application
abstract The invention belongs to the technical field of medicines, and particularly discloses a N- [8- (2-hydroxybenzoyl) amino ] caprylic acid monopotassium crystal compound, a preparation method and application. The crystal form compound has high purity, low impurity content, good stability, difficult moisture absorption and good fluidity. The crystal form compound can be used for preparing solid oral preparations such as capsules, tablets and the like with compounds with pharmaceutical activity such as micromolecules or polypeptides and the like, and the oral bioavailability of the medicine in the preparation is improved. Meanwhile, the bioavailability of the compound with pharmaceutical activity can be further improved by using the composition of the crystal form compound and sodium ion organic or inorganic salt.
priorityDate 2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558802
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14797
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23669833
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8900
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579247
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457728772
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID516892
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487106
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID379
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396401
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559508
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5462222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425953283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513958
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559554
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID923
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393644
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451113849
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425290545
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8058
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3776
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453034310
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID119389
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410697574
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87078746

Total number of triples: 48.